235 related articles for article (PubMed ID: 12640556)
21. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods.
Kroep JR; Van Groeningen CJ; Cuesta MA; Craanen ME; Hoekstra OS; Comans EF; Bloemena E; Hoekstra CJ; Golding RP; Twisk JW; Peters GJ; Pinedo HM; Lammertsma AA
Mol Imaging Biol; 2003; 5(5):337-46. PubMed ID: 14630513
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
Tseng J; Dunnwald LK; Schubert EK; Link JM; Minoshima S; Muzi M; Mankoff DA
J Nucl Med; 2004 Nov; 45(11):1829-37. PubMed ID: 15534051
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
24. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
25. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
26. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
Torizuka T; Zasadny KR; Recker B; Wahl RL
Radiology; 1998 Jun; 207(3):767-74. PubMed ID: 9609902
[TBL] [Abstract][Full Text] [Related]
27. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
28. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer.
Hallett WA; Marsden PK; Cronin BF; O'Doherty MJ
Eur J Nucl Med; 2001 Jul; 28(7):919-22. PubMed ID: 11504091
[TBL] [Abstract][Full Text] [Related]
29. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods.
Izquierdo-Garcia D; Davies JR; Graves MJ; Rudd JH; Gillard JH; Weissberg PL; Fryer TD; Warburton EA
Stroke; 2009 Jan; 40(1):86-93. PubMed ID: 18927453
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
31. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours.
Sadato N; Tsuchida T; Nakaumra S; Waki A; Uematsu H; Takahashi N; Hayashi N; Yonekura Y; Ishii Y
Eur J Nucl Med; 1998 Jun; 25(6):559-64. PubMed ID: 9618569
[TBL] [Abstract][Full Text] [Related]
33. Does whole-body Patlak
Fahrni G; Karakatsanis NA; Di Domenicantonio G; Garibotto V; Zaidi H
Eur Radiol; 2019 Sep; 29(9):4812-4821. PubMed ID: 30689031
[TBL] [Abstract][Full Text] [Related]
34. (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone.
Installé J; Nzeusseu A; Bol A; Depresseux G; Devogelaer JP; Lonneux M
J Nucl Med; 2005 Oct; 46(10):1650-8. PubMed ID: 16204715
[TBL] [Abstract][Full Text] [Related]
35. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
37. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
39. Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions.
Kim DW; Kim CG
Clin Breast Cancer; 2013 Jun; 13(3):196-201. PubMed ID: 23083500
[TBL] [Abstract][Full Text] [Related]
40. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
